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Abstract
Background: Aged long-term care receivers are affected by various adverse skin conditions like pressure ulcers,
incontinence-associated dermatitis, dryness, intertrigo, and many more. Prevention of these skin problems and the
provision of general hygiene and skin care activities are key areas of nursing practice. Numerous condition-specific
guidelines are available and are implemented separately. On the other hand, there is huge overlap in terms of
etiology, pathogenesis, and prevention of the skin conditions mentioned above. This leads to fragmented practice
neglecting shared etiologies and prevention and treatment principles.
Methods: The overall aims of this trial are to test the feasibility and to estimate possible effects of the
implementation of a comprehensive skin care and prevention strategy targeting main nursing-relevant skin
problems at the same time. A two-arm cluster-randomized controlled trial will be performed in 20 nursing homes
randomly selected from the population of nursing homes of the state of Berlin, comparing skin care according to
the skin care and prevention strategy with standard skin care.
Discussion: It is expected that the implementation of this evidence-based skin care and prevention strategy will
reduce the incidence of pressure ulcers, incontinence dermatitis, and other skin problems frequently related to care
dependency. This trial will benefit individual patients and aged nursing home residents in general given the high
prevalence and incidence of the addressed skin conditions. Findings of this exploratory trial may lay the foundation
for a change in the development and evaluation of clinical standards and practices in general as it moves the
perspective from individual conditions to a more comprehensive view on overlapping or coexisting health
problems, in this case common skin conditions, in old-age long-term care receivers.
Trial registration: The study is registered at the German Clinical Trials Register https://www.drks.de/drks_web/
navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00015680 (Deutsches Register Klinischer Studien, or DRKS;
registration number: DRKS00015680, date of registration: January 29, 2019) and ClincialTrials.gov (registration
number: NCT03824886, date of registration: January 31, 2019).
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Background
The substantial impact of age-related skin conditions,
especially in old age, was recently emphasized in the lat-
est World Health Organization (WHO) World Report
on Ageing and Health [1]. The most common skin con-
ditions in aged and care-dependent patients with a
prevalence up to 99.1% in the long-term care setting are
dry and vulnerable skin (including pruritus) and fungal
infections with prevalences ranging from 14.3% to 64%
[2, 3]. Aged and care-dependent patients are at high risk
for developing pressure ulcers (PUs), skin tears (STs),
intertrigo, and incontinence-associated dermatitis (IAD)
[3, 4]. These are distinct clinical diagnoses, and
condition-specific clinical guidelines and best practice
recommendations are available [5–8]. On the other
hand, these adverse skin conditions show many similar-
ities in terms of etiology (e.g., skin fragility, immobility,
and care dependency), prevention, and treatment [9].
For decades, preventive strategies implemented in clin-
ical practice have addressed these particular skin condi-
tions and risks separately. For example, a PU prevention
policy exists in nearly every health-care institution today.
Evidence-based strategies to prevent IAD, STs, or xerosis
cutis are also increasingly developed. Based on local prior-
ities and perceived needs, these recommendations are
(partly) implemented or not. However, all of these distinct
approaches have the same aim: to enhance and maintain
skin integrity in aged and care-dependent people. Thus,
proposed interventions have a lot in common: avoidance
of skin-stressing insults (e.g., mechanical loading and safe
handling) [7, 8], provision of skin protection and care
(e.g., using protecting skin care products) [5, 7], moisturi-
zation of dry and cracked skin [6], and minimization of
prolonged and repeated exposures to irritation (e.g., urine,
stool, and surfactants from cleansing products) [5, 6].
Despite these shared commonalities, no overall
evidence-based practice guidance exists for daily skin
care in care-dependent elderly people. Facilities are chal-
lenged to implement fragmented, condition-specific
guidelines, neglecting shared etiologies and prevention
and treatment principles. Information overload and mul-
tiple and complex rules on the same topic have been
shown to be important barriers to the implementation of
evidence-based practice [10].
Skin care in general plays a fundamental role in daily
nursing practice. However, the goals of providing skin
care interventions do not always seem to be explicit
[11], leading to a huge unexplained variability of skin
care activities in daily practice [12, 13]. Research evi-
dence suggests that current skin care is not always bene-
ficial [14] and there seem to be misconceptions about
the actual mode of action of skin care interventions [11].
Recently, an evidence-based skin care and prevention
strategy was developed. The skin care strategy guides
nurses through the care process starting from assess-
ment to the allocation of targeted skin area interven-
tions, taking into account available evidence, best
practice, and guideline recommendations [15]. Imple-
mentation of the newly developed evidence-based skin
health-promoting strategy will improve nurses’ know-
ledge, skills, and confidence in a core area of nursing
practice. Additionally, it is assumed that the implemen-
tation of the skin care and prevention strategy will lead
to an improvement of skin conditions, skin health, qual-
ity of life (QoL), and safety of elderly nursing home resi-
dents. However, the feasibility of implementation of this
skin care and prevention strategy and its potential to in-
fluence assumed patient and intermediate outcomes
have to be demonstrated before its clinical effectiveness
can be examined on a larger scale.
Objective
The overall aim of this trial is to implement a comprehen-
sive and evidence-based skin care and prevention package
that addresses common and largely avoidable adverse skin
conditions in long-term care at the same time. The trial
will answer the following research questions:
 Does the implementation of a skin care and
prevention strategy reduce the incidence of PUs,
IAD, intertrigo, and STs and the severity of dry skin
in the intervention compared with the control
group?
 How do different skin care regimens influence
important skin barrier characteristics such as skin
surface pH, stratum corneum hydration (SCH), and
transepidermal water loss (TEWL)?
 Does the implementation of the skin care and
prevention strategy reduce itch and pain and
improve QoL?
 What are the effect sizes and intra-class correlation
coefficients (ICCs) of the outcomes mentioned
above?
 Is the implementation of a standardized skin care
and prevention strategy feasible? What are relevant
context factors?
Methods, design, and analysis
Design and setting
This exploratory study is a cluster-randomized prag-
matic investigator-blinded parallel-group trial. The
study will be conducted in a random sample of 20
out of 288 institutional long-term care facilities of the
federal state of Berlin, Germany. Inclusion started
April 2019 and the last nursing home resident will
complete the study March 2021.
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Nursing homes and participants
Eligibility criteria
The inclusion criteria at the institutional level are that
(1) participating nursing homes must express a clear
commitment to implement the skin care and prevention
strategy if assigned to the intervention group, (2) partici-
pating nursing homes must have a valid PU prevention
standard/algorithm in place, (3) only nursing homes pro-
viding written commitment to adherence to the trial
procedures regardless of the outcome of randomization
will be included, and (4) nursing homes have to have a
minimum bed size of n = 70.
The inclusion criteria at the resident level are (1) living
in the nursing home at the time of data collection, (2)
age of at least 65 years, (3) “care degree 2 or higher” ac-
cording to the German code book (Sozialgesetzbuch, or
SGB) XI, and (4) written informed consent (from the
resident or a legal representative). Residents at the end
of life or with any dermatological condition or skin in-
festation requiring dermatological treatment or with
known intolerance to any possible irritating product in-
gredients (e.g., urea or lactate buffer) or known hyper-
sensitivity to any product ingredients (e.g., sorbid acid or
cetylstearyl alcohol) will not be considered eligible.
Interventions at the nursing home level
PU and IAD prevention and basic hygiene and skin care
interventions are routinely delivered in German nursing
homes. Therefore, nursing homes conducting PU pre-
vention or other protective skin care activities (or both)
according to “usual practice” will serve as the control
group.
In the interventional nursing homes, a newly devel-
oped skin care and prevention strategy will be imple-
mented on top on the existing care standards [15]. The
skin care and prevention strategy will be delivered by
nurses and consists of following components. Based on
a comprehensive assessment, skin care will be provided.
Condition-specific strategies for cleansing and the use of
leave-on products will be given, including guidance on
frequency of conduct/application and required product
characteristics. For example, xerotic skin areas (e.g., ex-
tremities and feet) will be cleansed once daily or less
often in the case of severe dryness, and lipophilic
leave-on products, including humectants, will be applied
at least twice daily or more often if needed. Personal
care products will be used as long as they meet required
product characteristics. If products are not available, a
basic lipophilic emulsion (Lipophile Harnstoff Creme 5,
Neues Rezeptur Formularium (NRF) 11.129) [16] will be
delivered. Skin areas exposed to urine or feces (or both)
will be cleansed after each incontinence episode by using
mucosa-friendly mild cleansers, and a skin protection
product that may include various product types (e.g.,
polymers) will be applied. If no products are available, a
basic skin protectant (Weiche Zinkpaste DAB, NRF
11.21) [16] will be delivered and applied. Personal pref-
erences of the residents will be taken into account dur-
ing clinical decision making. The skin care and
prevention strategy contains clear guidance when to in-
volve medical experts. The components of this strategy
will be adapted to local requirements as necessary.
This skin care and prevention strategy will be imple-
mented by a combination of multiple strategies based on
the normalization process theory [17], a
socio-psychological middle-range theory which has been
proven to be an effective framework for guideline imple-
mentation in nursing practice [18]. In addition, existing
research evidence on the most relevant implementation
barriers and facilitators [19–21] will be taken into ac-
count. Also, attention will be given to the four-phase
model proposed by the German Network for Quality
Improvement for implementing the National Expert
Standards [22] because it is particularly relevant to the
German nursing context.
Strategies to improve adherence to intervention protocol
All implementation steps are designed to maximize
adoption. Throughout the trial, continual communica-
tion with nursing home managers in either study group
will be held to prevent early loss of clusters. Study visits
to the nursing home wards conducted for data collection
will maintain awareness and communication between
caregivers and the study team. Because nursing home
residents live in the institutions, there is a low risk that
they will not be available at study visits. Before any in-
clusions, kick - off meetings will be held in the partici-
pating nursing homes. Study background and
procedures are explained and the importance of follow-
ing the study protocol is emphasized. A key project
leader and additionally a “skin care team” per participat-
ing nursing home will be nominated and caregivers will
be trained. The “skin care team” ideally will consist of
three or four persons (e.g., quality manager, residential
sector manager, and wound manager). The study team
will support this team during the whole study (e.g., the
study team will set goals with the project team onsite
the nursing homes and will offer help at any time if
problems arise) and evaluate the implementation
process. Additionally, posters and flyers will be created
and placed in the nursing homes for caregiver, residents,
their relatives and legal representatives.
Participant timeline
In total, four study visits are planned. After inclusion,
residents will be followed up for 24 ± 1 weeks. Written
informed consent will be obtained from the residents
themselves or their legal representatives prior to study
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participation. All participating nursing home residents
undergo a comprehensive demographic, nursing, med-
ical, and dermatological examination. A detailed planned
study schedule is shown in Fig. 1.
Outcomes and measurements
Owing to the exploratory and pragmatic nature of this
trial, a broad range of outcomes will be measured. The
main clinical outcomes are PU, IAD, intertrigo, and ST
incidence and skin dryness per skin area. Fig. 2 shows
the time points of measurement. All outcomes will be
measured at baseline (week 0) and after 3 months (week
12 ± 1) and after 6 months (week 24 ± 1).
Dermatological examination
PU incidence and location will be classified in accordance
with the National Pressure Ulcer Advisory Panel/European
Pressure Ulcer Advisory Panel (2014) [23]. The IAD inci-
dence will be classified in accordance with GLOBIAD
(Ghent Global IAD Categorisation tool) [24], and coded ac-
cording ICD 11 (EK02.22) and the distinction between in-
tact and eroded skin will be classified in accordance with
the Proceedings of the Global IAD Expert Panel [5]. Inter-
trigo incidence and location will be classified in accordance
with ICD 11 (EK02.2), and the ST incidence and location
will be classified in accordance with the International Skin
Tear Advisory Panel [25].
Dry skin per skin area will be classified in accordance
with the overall dry skin (ODS) score [26, 27]. The ODS
score is a clinical assessment of the presence and severity of
skin dryness using a five-point scale. A score of 0 indicates
no skin dryness whereas a score of 4 indicates advanced
skin roughness, large scales, inflammation, and cracks [26].
Skin physiology measurements
In addition, skin function will be assessed by measuring
SCH, TEWL, and skin surface pH, which are established
parameters to characterize the skin barrier function and
Fig. 1 Study schedule
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which have been used successfully in a similar trial in
this setting [28].
SCH will be measured by using the Corneometer CM
825 (Courage + Khazaka, Cologne, Germany). This meas-
urement is based on the differences of the dielectric con-
stant of water and other substances. With this device, only
the moisture content in the stratum corneum is measured
[29]. The arbitrary units range from 0 to 120, and higher
readings indicate higher SCH.
TEWL will be measured with the Tewameter TM 300
(Courage + Khazaka). The probe captures the constant
permeation of water through the stratum corneum in
grams per hour per square meter [30]. The measuring
probe contains a pair of sensors that are located at dif-
ferent distances from the skin surface to determine
temperature and relative humidity above the skin sur-
face. The humidity gradient between both sensors is
used for calculating the TEWL. Higher values indicate a
higher TEWL. Skin surface pH will be measured with
the Skin-pH-Meter® PH 905 (Courage + Khazaka), a pla-
nar glass electrode. pH is a measure of acidity and alka-
linity of a solution and it indicates the concentration of
the hydrogen ions in an aqueous solution [31]. Reference
values of human skin have been reported to range from
4 to 6 [32, 33].
The skin surface temperature of the skin areas will be
recorded as well. It will be measured with the
Skin-Thermometer ST 500 (Courage + Khazaka) in de-
grees Celsius.
Resident-reported outcome measures
QoL in residents without cognitive impairment will be
assessed with the WHO - Five Well-being Index [34]
and QUALIDEM [35] for residents with dementia. The
Fig. 2 Timeline of screening and study visits
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German version of the WHO - Five Well-Being Index
questionnaire published by the WHO in 1998 will be
used. Scores range from 5 (all the time) to 0 (never) for
a total of five items. Simple questions will be asked re-
garding well-being in the previous two weeks (e.g., “In
the last two weeks … I was happy” or “… I was relaxed”).
The sum scores range from 0 (indicating the lowest
well-being) to 25 (indicating the highest well-being). A
cutoff score of not more or equal than 13 is
recommended.
The QUALIDEM assessment is a dementia-specific
QoL instrument that is carried out by the nursing staff
and that allows a proxy-based QoL rating in all stages of
dementia. The German version of the QUALIDEM (ver-
sion 2.0) published in 2015 will be used to assess the
QoL of the resident of the previous seven days [35]. If
the resident is affected by a mild to severe dementia, the
37-item assessment will be used. For residents with very
severe dementia the 18-item instrument will be used. To
assess whether the resident is affected by mild to severe
dementia or very severe dementia, the global deterior-
ation scale (GDS) will be used [36]. GDS scores from 2
to 6 indicate a mild to severe dementia, and the 37-item
assessment of the QUALIDEM tool will be used. A GDS
score of 7 indicates very severe dementia, and the
18-item QUALIDEM tool will be used.
Itch will be assessed with the 5-D Itch scale [37]. The
score of the 5-D Itch scale ranges from 5 (no pruritus)
to 25 (most severe pruritus) and contains five items
measuring pruritus over the previous two weeks. Pain
will be assessed with a numeric rating scale by residents
without cognitive impairments and with a verbal rating
scale by residents with cognitive impairments [38].
Baseline assessment and covariates
Demographic variables (age, sex, care level, and highest
educational level), main medical diseases, and medica-
tions will be obtained from medical records by trained
study assistants. Data regarding skin self-care ability, in-
continence and type will be obtained from the medical
records or, if possible, via interview of the nursing home
residents or the caregivers.
Functional assessments using the Braden scale and
Barthel - Index will be conducted. The Braden scale is a
six-item pressure ulcer risk assessment score with scores
ranging from 6 (high-pressure ulcer risk) to 23 (no-pres-
sure ulcer risk). The Barthel - Index measures physical
function related to the daily activities using 10 items
(e.g., washing and toilet use, eating and mobility or in-
continence). Scores range from 0 (very dependent) to
100 (not dependent) [39].
All residents will be interviewed regarding their skin
care habits. Data will be documented in structured
source documents by trained study assistants. Variables
for assessing skin care routine will be (1) washing habits,
(2) showering habits, (3) bathing habits, (4) moisturizing
habits of the face and body, (5) hair care, and (6) shaving
habits. For all variables, the frequency, skin areas, used
skin care products, and the residents’ ability to apply
skin care by themselves will be documented. In case of
cognitive impairment of the resident, the respective
nurse will be asked or the information will be obtained
from the medical records.
The residents or their caregivers will be asked regard-
ing the date of the last visit by physician/specialty in
week 0. If possible, the following information will ob-
tained from the medical records:
(1) Is there a documentation of pressure ulcer risk in
place?
(2) Are skin assessment results documented?
(3) If applicable, the type of pressure ulcer preventive
mattress or seating cushion;
(4) The repositioning interval if bedfast;
(5) Seating hours if not able to stand up independently;
(6) Off-loading of heels if exposed to high risk of
pressure ulcer;
(7) Skin care interventions provided (cleansing and
leave-on products);
(8) Use of incontinence products and types;
(9) Incontinence skin care products.
To assess the degree of implementation of the skin
care package and possible moderating or mediating ef-
fects of context factors, further quantitative and qualita-
tive data will be gathered at resident, staff, and
institutional levels for process evaluation [40]. The
protocol of this mixed methods study embedded in the
trial will be reported separately elsewhere.
Randomization and recruitment
A 1:1 simple random generation of the allocation se-
quence of nursing homes to intervention (n = 10) or
control group (n = 10) will be undertaken by an inde-
pendent data manager via a computer-generated random
list. The allocation will be conducted by the investigator
using numbered opaque envelopes (1 to 20) containing
computer-generated random numbers.
Nursing homes will be randomly selected from a com-
prehensive list of all nursing homes in Berlin (n = 288).
Potentially eligible nursing homes will be contacted and
invited to participate by letter. If there is no response by
a defined deadline, the next randomly selected nursing
home will be invited. If applicable, baseline characteris-
tics (e.g., number of beds) of non-responders and rea-
sons for non-participation will be listed in order to
estimate a possible selection bias. In the case of small
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institutions with fewer than 70 beds/residents, the next
randomly selected institution will be invited.
Recruitment of the nursing home residents and base-
line measurements will be completed prior to random
allocation of the nursing homes. Posters and flyers will
be placed in public areas in the nursing homes to inform
residents and relatives as a first step. The recruitment
onsite the nursing homes will be carried out in close co-
operation with a nominated key project leader of the
participating nursing home. The key project leader will
inform possible residents and hand out information leaf-
lets or letters. Interested residents or their legal repre-
sentatives will be contacted by the study team personally
and will be invited to participate in the study.
Blinding
One group of investigators and study nurses administers
the interventions and communicates with participating
nursing homes. A second independent group of outcome
assessors (including dermatologists/residents of derma-
tology) will complete the dermatological assessments
while blinded to the allocation. The data manager and
trial statistician will be blinded during data management
and statistical analysis.
Sample size calculation
Because the trial is exploratory in nature, a primary out-
come is not defined. The sample size is determined such
that the power of statistical tests is sufficiently high for
each of several binary and continuous outcomes under
realistic assumptions. According to the federal state gov-
ernment, there are 288 nursing homes in Berlin. Accord-
ing to the latest statistics (2015), the total number of
nursing home residents in Berlin is 28,299. Given a
mean of 100 residents per institution and a participation
rate of 25%, the expected total number of residents is 25
per participating institution (500 in total). Taking into
account a drop - out rate of 8%, each participating nurs-
ing home contributes about 23 residents to the trial. If
m = 10 nursing homes are included in each study arm
and given an ICC of ρ = 0.02 [41] and an incidence for
the skin conditions of around pC = 50% per annum (p.a.)
(29.3% in 6 months) in the control group, the two-sided
Z-test for difference in proportions at a level of α = 0.05
has a power of more than 80% if in the experimental
group skin condition worsens in less than pE = 29.8%
p.a. (16.2% in 6 months). The power calculation for the
clustered binary outcome was carried out using the
method described in Ahn et al. [42]. For metrical out-
comes such as the ODS score, the two-sided t-test can
detect a minimal effect size (Cohen’s d) of d = 0.33 with
a power of 80% at a significance level of α = 0.05. Again,
an ICC of ρ = 0.02 is assumed. Therefore, the detectable
effect sizes are relatively small for all outcomes. Since
the effects of the experimental skin care regimen are ex-
pected to be larger, the study is not underpowered for
each variable.
Statistical analysis
All statistical evaluations will be conducted by using the
statistical programming language R and IBM SPSS sta-
tistics (IBM Corporation, Armonk, NY, USA). Variables
will be described at the cluster (nursing homes) and in-
dividual level on an intention-to-treat basis. A two-level
analysis will be conducted for all outcomes. For compar-
isons of event rates in the control and experimental
groups, we will use appropriate generalized
mixed-effects models. Furthermore, for all outcomes,
ICCs will be calculated providing a basis for future sam-
ple size estimation in a subsequent confirmatory trial.
The two-sided level of significance is α = 0.05. All p
values will be considered exploratory, no adjustment of
the level of significance will be performed, and no in-
terim analysis is planned. The data collected for process
evaluation will be analyzed descriptively. The main aim
of the trial is to provide a solid basis for a subsequent
confirmatory trial.
Analysis population
The statistical analysis will be run on the basis of the
intention-to-treat principle. At the cluster level, the
study population includes all nursing homes which have
been randomly assigned. At the individual level, it con-
tains all residents of the randomly assigned nursing
homes who meet the inclusion criteria and who have
passed the baseline visit. Nursing home residents who
stay for longer than 2months outside the nursing homes
(e.g., due to hospital admission), die, or leave the nursing
home during the study period will be analyzed until that
time point (early termination).
Trial advisory board
A trial advisory board has been implemented. On Janu-
ary 14, 2019 a face-to-face meeting was conducted with
all advisory board members listed in Table 1. The design,
conduct, feasibility, and aims were discussed with all ad-
visory board members, and the study protocol was re-
vised and improved on the basis of the expert
recommendations. During the trial, the advisory board
will oversee the study progress (including recruitment),
review results of the monitoring reports, and provide
recommendations on possible safety issues.
Data management
A paper case report form (pCRF) file will be created for
the study. Data (informed consent process and consent
retrieval; demographics; medical history; clinical examin-
ation; measurements of skin functional parameters;
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clinical scores; occurrence of PU, IAD, xerosis cutis, ST,
and intertrigo; compliance; delivery and return of the
skin care diary; and delivery of products if applicable)
will be recorded in written form during the study visits.
An electronic case report form (eCRF) will be developed
by the Charité Coordinating Center for Clinical Trials at
the Charité-Universitätsmedizin Berlin (KKSC). Data
from the pCRF will be extracted and entered into an
eCRF. Data management and handling of data will be
conducted in accordance with the trial-specific data
management plan and the International Conference on
Harmonisation (ICH) guidelines.
Data entry will be performed by the trial site personnel.
According to a pre-defined query process, changes to data
entries in the eCRF (if any) will be made at the site by the
qualified trial site personnel. The eCRF will have an audit
trail with appropriate functionality for data capture, track-
ing, and documentation of any queries or changes. Elec-
tronic signatures will be used to verify the data and
identify the person entering or changing the data.
Data monitoring
Monitoring of the study is the responsibility of the investi-
gator and will be undertaken by an independent monitor
from the KKSC. The monitor is responsible for reviewing
the progress of the study and for verifying adherence to the
protocol as well as compliance to ICH Good Clinical Prac-
tice and also for handling any problems that arise. The
monitor will visit the center before, during, and after com-
pletion of the study to ensure that the study is conducted,
recorded, and reported in accordance with the protocol.
Harms
This is neither a drug nor a medical device study. The
used or provided skin care products (or both) may be
regarded as cosmetic products according to EU Regula-
tion Number 1223/2009 on cosmetic products. In
addition, long-term care residents are affected by a
variety of diseases and medical problems. Therefore, the
terminology of undesirable effects and serious undesir-
able effects will be adopted for this trial and will be used
for the documentation throughout the study.
Discussion
To the best of our knowledge, this is the first trial imple-
menting a comprehensive evidence-based skin care and
prevention strategy in institutional long-term care. The
skin care and prevention strategy was developed system-
atically, taking currently available evidence and expert
opinion into account. Given the novelty of this approach
and its complexity, first an exploratory trial is needed in
order to evaluate the feasibility of this intervention pack-
age and possible trial procedures and to gain insights
into potential mechanisms of change and impacts on
patient-important outcomes. Trial results will have im-
pacts on clinical research and practice: In the short term,
results will (1) prove the feasibility of the intervention
package and provide robust data about relevant context
factors and required implementation strategies to be
considered for a confirmatory evaluation of the skin care
program’s clinical effectiveness and cost-effectiveness
and (2) inform the protocol for subsequent confirmatory
trials (e.g., in regard to the responsiveness of outcome
measures and associated effect sizes, ICCs, and data col-
lection methods).
This trial will benefit individual patients and aged
nursing home residents in general. According to the lat-
est systematic reviews and researching [2, 3], the skin
conditions of interest are frequent in this population: In
German long-term and geriatric care facilities, the PU
prevalence is approximately 4% [43–45], the prevalence
of dry skin is approximately 53% [46] and associated
pruritus up to 14% [46, 47], and the prevalence of IAD
ranges from 4% to 11% [48, 49]. The incidence and se-
verity of these skin conditions will be reduced; thus, pa-
tient safety will be enhanced. The improvement of dry
Table 1 Trial advisory board members and affiliations
Name Roles and affiliations
Dimitri Beeckman Professor of skin integrity and clinical nursing and visiting professor at Örebro University (Sweden),
Royal College of Surgeons in Ireland (Ireland), and University Centre for Nursing and Midwifery, Ghent
University, Belgium
Lisette Schoonhoven Professor of nursing science, University Medical Center, Utrecht, the Netherlands
Ulrike Blume-Peytavi Vice director of the Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Germany,
and director of the Clinical Research Center for Hair and Skin Science at the Department of Dermatology
and Allergy, Charité-Universitätsmedizin Berlin, Germany
Ursula Müller-Werdan Director of the Evangelic Geriatric Center, Research Group Geriatrics, Charité-Universitätsmedizin Berlin, Germany
Andreas Büscher Professor of nursing science and scientific director of the German Network for Quality Development in Nursing,
Osnabrück, Germany
Gabriele Meyer Professor of health and nursing science, Department of Health and Nursing Science, Martin-Luther University Halle,
Wittenberg, Germany
Ingeborg Simon Patient representative and member of the senior advisory council, Berlin, Germany
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skin helps to prevent secondary infection and pruritus.
Overall, QoL will be increased. Potential unhelpful care
interventions will be avoided. Carefully developed and
targeted skin care practice will reduce patients’ exposure
to unnecessary and inappropriate products, thus redu-
cing the risk of irritation, contact allergies, and other ad-
verse effects [11]. In addition, so far, often neglected and
overlooked age-related skin conditions , especially symp-
tomatic xerosis cutis, which is an explicitly stated unmet
need of aged patients [50], will be addressed.
Findings of this exploratory trial may lay the founda-
tion for a change in the development of clinical stan-
dards and practices in general as it moves the
perspective from focusing on individual conditions to a
more comprehensive view on overlapping or coexisting
health problems, in this case common skin conditions,
in old-aged long-term care receivers. This helps to pool
resources and to increase overall patient safety within
health-care institutions and to increase professional
competencies of nurses, who have the major responsibil-
ity in aged care.
Trial status
This trial is registered at the German Clinical Trials
Register and ClincialTrials.gov. The local ethics commit-
tee (EA1/243/18) approved the study on January 11,
2019. At the time of submission of this manuscript, the
recruitment of the nursing homes had been started. The
first 12 nursing homes expressed interest. Of them, six
nursing homes committed to participation and were in
preparation to start the study in April and June 2019.
Six other nursing homes have confirmed appointments
for the first information meetings.
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